Mantle cell lymphoma is a rare and incurable lymphoproliferative disorder. In the
MCL01 trial, patients were treated with the R-HCVAD regimen [rituximab plus
HyperCVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone; R-CVAD) alternating with high-dose methotrexate and cytarabine
(AM)] for four cycles followed by autologous stem cell transplantation (ASCT) for
those who reached only a partial response. After a median follow-up of 105 years,
we reported 10-year progression-free and overall survival rates of 35% and 61%
respectively, with a 10-years cumulative incidence rate of second malignancies of
106%. Mature results of the MCL01 trial confirmed the efficacy of HyperCVADAM as a frontline regimen for younger patients (≤65 years).